RT Journal Article
T1 Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set.
A1 Grothey, Axel
A1 Yoshino, Takayuki
A1 Bodoky, Gyorgy
A1 Ciuleanu, Tudor
A1 Garcia-Carbonero, Rocio
A1 García-Alfonso, Pilar
A1 Van Cutsem, Eric
A1 Muro, Kei
A1 Mytelka, Daniel S
A1 Li, Li
A1 Lipkovich, Olga
A1 Hsu, Yanzhi
A1 Sashegyi, Andreas
A1 Ferry, David
A1 Nasroulah, Federico
A1 Tabernero, Josep
K1 bevacizumab
K1 electronic medical records
K1 neutropenia
K1 prognostic
K1 ramucirumab
AB In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. Thus, we conducted an exploratory post-hoc analysis of RAISE and a retrospective, observational analysis of electronic medical record (EMR) data to determine and verify the association of neutropaenia, baseline absolute neutrophil count (ANC) and survival. The RAISE analysis used the study safety population (n=1057). IMS Health Oncology Database (IMS EMR) was the source for the real-world data set (n=617). RAISE patients with treatment-emergent neutropaenia had improved mOS compared with those without (ramucirumab arm: 16.1 vs 10.7 months, HR=0.57, p Neutropaenia during treatment, and subsequent dose modifications or discontinuations, do not compromise treatment efficacy. Baseline ANC is a strong prognostic factor for survival and is associated with treatment-emergent neutropaenia in the analysed population. NCT01183780, Results.
SN 2059-7029
YR 2018
FD 2018-04-24
LK https://hdl.handle.net/10668/25594
UL https://hdl.handle.net/10668/25594
LA en
DS RISalud
RD Apr 17, 2025